{
    "clinical_study": {
        "@rank": "102542", 
        "arm_group": [
            {
                "arm_group_label": "Amoxicillin/Clavulanic Acid and Lacidofil\u00ae STRONG", 
                "arm_group_type": "Experimental", 
                "description": "Participants are provided in double blinded fashion Lacidofil\u00ae STRONG to take with antibiotics"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Participants are provided in double blinded fashion placebo to take with antibiotics"
            }
        ], 
        "brief_summary": {
            "textblock": "The objectives of this study are to evaluate stool consistency and stool frequency during\n      and up to 8 weeks following a 7 day antibiotic treatment with Amoxicillin/Clavulanic Acid\n      875mg BID."
        }, 
        "brief_title": "Effect of a Lacidofil\u00ae STRONG in Healthy Adults Taking Antibiotic Treatment", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": "Antibiotic Associated Diarrhea", 
        "condition_browse": {
            "mesh_term": "Diarrhea"
        }, 
        "detailed_description": {
            "textblock": "It is hypothesized that the proportion of subjects having a diarrhea-like defecation,\n      defined as a stool frequency \u2265 3 per day and/or stool consistency \u2265 5 (Bristol Stool Score)\n      for at least 2 days will be lower in the group receiving Lacidofil\u00ae STRONG compared to the\n      group receiving placebo and therefore mean Bristol Stool Scores will be lower in subjects\n      receiving Lacidofil\u00ae STRONG compared to those receiving placebo."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female aged 18 to 50 years inclusive\n\n          -  Body mass index 18.0 - 29.9 kg/m2\n\n          -  Healthy as determined by laboratory results, medical history and physical   exam\n\n          -  Agrees to comply with study procedures\n\n          -  Agrees not to change current dietary habits (with the exception of avoiding pro- and\n             prebiotics) and activity/training levels during the course of the study\n\n          -  Has given voluntary, written, informed consent to participate in the study\n\n        Exclusion Criteria:\n\n          -  Women who are pregnant, breastfeeding, or planning to become pregnant during the\n             course of the trial\n\n          -  Body mass index \u2265 30 kg/m2\n\n          -  Average number of formed bowel movements > 3 per day or < 3 per week\n\n          -  Participation in a clinical research trial within 30 days prior to randomization\n\n          -  Use of antibiotics within 60 days prior to randomization.\n\n          -  Habitual use of pro- and/or prebiotic products.  Subjects must not consume foods or\n             supplements containing added pro- and/or prebiotics within 3 weeks prior to\n             randomization and during the course of the study\n\n          -  Use of laxatives, enemas or suppositories 1 week prior to randomization and for the\n             duration of the study\n\n          -  Follows a vegetarian or vegan diet\n\n          -  Unstable medical conditions, as determined by the Qualified Investigator\n\n          -  History of chronic gastrointestinal disorders including irritable bowel syndrome;\n             chronic constipation; chronic diarrhea; dyspepsia; gastroesophageal reflux disease;\n             diverticulitis; colitis; Crohn's disease; or any other malabsorption or\n             gastrointestinal disorder\n\n          -  Subjects with an immuno-compromised condition (e.g. AIDS, lymphoma, patients\n             undergoing long-term corticosteroid treatment)\n\n          -  Alcohol use > 2 standard alcoholic drinks per day and/or alcohol or drug abuse within\n             past year\n\n          -  Allergy or sensitivity to test product ingredients or Amoxicillin/Clavulanic Acid\n\n          -  Individuals who are cognitively impaired and/or who are unable to give informed\n             consent\n\n          -  Any other condition which in the Investigator's opinion may adversely affect the\n             subject's ability to complete the study or its measures or which may pose significant\n             risk to the subject"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01941160", 
            "org_study_id": "13LAHL"
        }, 
        "intervention": [
            {
                "arm_group_label": "Amoxicillin/Clavulanic Acid and Lacidofil\u00ae STRONG", 
                "description": "Lacidofil\u00ae STRONG capsule twice daily", 
                "intervention_name": "Lacidofil\u00ae STRONG", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo capsule twice daily", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Anti-Bacterial Agents", 
                "Antibiotics, Antitubercular"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 12, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "N6A 5R8"
                }, 
                "name": "KGK Synergize Inc."
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Placebo Controlled, Parallel Group Study to Evaluate the Effect of a Probiotic Product, Lacidofil\u00ae STRONG, in Healthy Adults Taking Antibiotic Treatment", 
        "other_outcome": {
            "description": "Assessed by measurement of biometrics, vital signs, general blood chemistry and complete blood counts", 
            "measure": "Safety profile of Lacidofil\u00ae STRONG", 
            "safety_issue": "No", 
            "time_frame": "Up to 14 days"
        }, 
        "overall_official": {
            "affiliation": "KGK Synergize Inc.", 
            "last_name": "Dale Wilson, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Canada: Health Canada"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "The primary outcomes are the between group difference in mean Bristol Stool Scores (consistency) and the between group difference in the mean number of bowel movements (frequency).", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 63 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01941160"
        }, 
        "responsible_party": {
            "investigator_affiliation": "KGK Synergize Inc.", 
            "investigator_full_name": "Dale Wilson, MD", 
            "investigator_title": "Medical Director", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Proportion of subjects having diarrhea-like defecation defined as a stool frequency \u2265 3 per a 24 h period and/or stool consistency \u2265 5 (Bristol Stool Score) for at least 2 days (48 h period)", 
                "measure": "Incidence of AAD", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 63 days"
            }, 
            {
                "description": "Assessed by Gastrointestinal Symptom Rating Scale (GSRS) questionnaire, bowel habits, adverse effects", 
                "measure": "Influence of Lacidofil\u00ae STRONG on side effects associated with antibiotic use", 
                "safety_issue": "No", 
                "time_frame": "Up to 63 days"
            }
        ], 
        "source": "KGK Synergize Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Lallemand Health Solutions", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "KGK Synergize Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}